Clinical Trial Update: A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer [NA]

View source ↗

Summary

This clinical trial is evaluating sirolimus albumin-bound in combination with palbociclib and fulvestrant for advanced HR-positive, HER2-negative breast cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Palbociclib (palbociclib)
• Sirolimus (Albumin-Bound) (sirolimus)

Snippet

Sponsor: Fudan University | Conditions: Advanced HR - Positive, HER2 - Negative Breast Cancer, Resistant to (Neo)Adjuvant Endocrine Therapy | NA | Status: RECRUITING